Serendipity: How the search for meaning of serum uric acid might lead to the repurposing of an old drug in patients with cardiovascular disease

Abstract

Get full access to this article

View all access options for this article.

References

Lazzeroni D, Bini M, Camaiora U, et al. Serum uric acid level predicts adverse outcomes after myocardial revascularization or cardiac valve surgery. Eur J Prev Cardiol. 2018; 25: 119–126.

Grassi

Ferri

Desideri

et al.

Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des 2013; 19: 2432–2438.

Taghizadeh

Vonk

Boezen

. Serum uric acid levels and cancer mortality risk among males in a large general population-based cohort study. Cancer Causes Control 2014; 8: 1075–1080.

Bennett

Holmes

. Mendelian randomisation in cardiovascular research: An introduction for clinicians. Heart 2017; 11: 1–8.

Reginato

Mount

Yang

et al.

The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012; 8: 610–621.

Keenan

Zhao

Rasheed

et al.

Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol 2016; 67: 407–416.

Palmer

Nordestgaard

Benn

et al.

Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ 2013; 347: f4262–f4262.

Pfister

Barnes

Luben

et al.

No evidence for a causal link between uric acid and type 2 diabetes: A Mendelian randomisation approach. Diabetologia 2011; 54: 2561–2569.

Zalawadiya

Veeranna

Mallikethi-Reddy

et al.

Uric acid and cardiovascular disease risk reclassification: Findings from NHANES III. Eur J Prev Cardiol 2015; 4: 513–518.

10.

Lioté

. Recent developments in crystal-induced inflammation pathogenesis and management. Curr Rheumatol Rep 2007; 9: 243–250.

11.

Ridker

Everett

Thuren

et al.

Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131.

12.

Nidorf

Eikelboom

Budgeon

et al.

Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61: 404–410.

13.

Wei

Mackenzie

Chen

et al.

Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 2011; 71: 600–607.

14.

Singh

Ramachandaran

et al.

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord 2017; 17: 76–76.

15.

MacIsaac

Salatzki

Higgins

et al.

Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension 2016; 67: 535–540.

16.

Struthers

Donnan

Lindsay

et al.

Effect of allopurinol on mortality and hospitalisations in chronic heart failure: A retrospective cohort study. Heart 2002; 87: 229–234.

17.

Singh J and Cleveland J. Allopurinol and the risk of incident peripheral arterial disease in the elderly: A US Medicare claims data study. Rheumatology (Oxford). Epub ahead of print 3 July 2017. DOI: 10.1093/rheumatology/kex232.

18.

Taggart

Young

Hooper

et al.

Lack of cardioprotective efficacy of allopurinol in coronary artery surgery. Br Heart J 1994; 71: 177–181.

19.

Grainger R and Taylor WJ. Allopurinol and peripheral vascular disease: Enough observational data to warrant interventional studies Allopurinol and the prevention of vascular disease. Rheumatology (Oxford). Epub ahead of print 14 September 2017. DOI: 10.1093/rheumatology/kex354.

20.

Satoh

. Development of novel therapies for cardiovascular diseases by clinical application of basic research. Circ J 2017; 81: 1557–1563.